Asset Details
Do you wish to reserve the book?
Homotaurine in Parkinson’s disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Homotaurine in Parkinson’s disease
Do you wish to request the book?
Homotaurine in Parkinson’s disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Homotaurine in Parkinson’s disease
2015
Overview
Homotaurine is a natural compound of red algae, which has been demonstrated to have a neuroprotective effect and has been evaluated as a possible therapeutic agent for Alzheimer’s disease. This was a single blind, randomized, controlled study to evaluate the safety and efficacy of homotaurine in patients with Parkinson’s disease (PD) and cognitive impairment. Patients were evaluated at baseline and 6 months later. Assessments included, the evaluation of: motor and non-motor conditions and complications (Unified Parkinson’s Disease Rating Scale, UPDRS); disability and quality of life; depression; excessive daytime sleepiness and fatigue. An extensive neuropsychological tests battery was administered evaluating specific cognitive domains: memory, phonemic verbal fluency, executive functions and selective visual attention. After baseline testing, patients were allocated to one of the two groups: (A) treatment group: patients treated with homotaurine 100 mg; (B) control group: patients not treated with homotaurine. Forty-seven patients were evaluated at baseline, 24 (51 %) completed the study (PD-homotaurine:
n
= 11; 44 % and PD-controls:
n
= 13; 59 %); discontinuation rate was similar across subjects (
p
= 1.0). Intention to treat analyses to evaluate homotaurine safety showed mild side effects (gastrointestinal upsetting) in 3 patients. Per protocol analyses of homotaurine efficacy showed no difference between groups. Within group analyses showed that PD-homotaurine patients had better score at UPDRS-I at the end of the study compared to baseline (
p
= 0.017) and at Epworth Sleepiness Scale (
p
= 0.01). No other differences were found. No significant difference arose for the PD-ctrl group. Homotaurine is a safe drug. Our data suggest a beneficial effect of homotaurine on excessive sleepiness. Future studies are encouraged to confirm this promising role of homotaurine in promoting the sleep/awake cycle in patients with PD.
Publisher
Springer Milan,Springer Nature B.V
Subject
/ Antiparkinson Agents - adverse effects
/ Antiparkinson Agents - therapeutic use
/ Cognition Disorders - drug therapy
/ Cognition Disorders - etiology
/ Cognition Disorders - physiopathology
/ Disorders of Excessive Somnolence - drug therapy
/ Disorders of Excessive Somnolence - etiology
/ Disorders of Excessive Somnolence - physiopathology
/ Female
/ Humans
/ Male
/ Medicine
/ Parkinson Disease - complications
/ Parkinson Disease - drug therapy
/ Parkinson Disease - physiopathology
/ Parkinson Disease - psychology
